Ophtec Secures CE Marking for Aspheric Presbyopia-Correcting IOL

May 12, 2017: By Jon Swedien

OphtecOphtec has received CE marking for its Precizon Presbyopic, a new aspheric presbyopia-correcting IOL, the Netherlands company announced May 6.

The lens will be commercially launched in October 2017 during the annual conference of the European Society of Cataract and Refractive Surgeons in Lisbon, Portugal.

The product will initially be available in the European Union and a few selected markets, Ophtec said.

The Precizon Presbyopic IOL features a patent-pending continuous transitional focus (CTF) optical design.

The CTF design’s transitional zones offer a smooth, continuous transition from near to infinity vision, enabling surgeons to treat a wider range of presbyopic patients with confidence, Ophtec said.

The IOL appears to be able to forgive larger degrees of lens tilt and decentration, and this tolerance reduces photic phenomena, helping patients to adapt more naturally to their new vision, Ophtec said.

The lens is also designed to be less dependent on pupil size under all lighting conditions, Ophtec said.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Refocus Completes PMA Application for VisAbility as Treatment for Presbyopia

Novaliq’s NovaTears+Omega-3 Approved in Europe for Dry Eye

CooperVision Acquires Paragon Vision Sciences for $80 Million

AYOXXA Biosystems Launches Test for Biomarkers in Retinal Disease

Glaukos Announces New Patent for Glaucoma Stent Implanted in Schlemm’s Canal

Fortress Biotech Forms Tamid Bio Subsidiary; Lead Candidate is Ophthalmic Gene Therapy for MPS I

Samsung Launches App that Adjusts QLED TV Settings for Color-blind Viewers

Solar Eclipse Burns Crescent Wound in Woman’s Unprotected Retina

US Judge Refuses to Dismiss Allergan Suit against Imprimis

BioLight Sells IOPtima to Chengdu Kanghong Pharmaceutical Group for $56 Million

Regeneron Ending Eylea, Nesvacumab Combo Program

UK Retinal Drugmaker Exonate Forms Clinical Advisory Board

US FDA Approves RxSight’s Light Adjustable Lens and Light Delivery Device

EMA to Move to Amsterdam due to Brexit

First Subject Dosed in Nevakar’s Phase III Trial of NVK-002 for Myopia in Children

ProQR Doses First Patient in Phase I/II Trial for Leber’s Congenital Amaurosis 10

Aston EyeTech Raises $6.6 Million in Series A Equity Round

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022